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Objectives. To examine the efficacy and safety of Prosaptide
TM (PRO) for the treatment of painful HIV-associated sensory
neuropathies (HIV-SN). Design. A randomized, double-blind, placebo-controlled, multicenter study in participants with
sensory neuropathy. Pain modulating therapy was discontinued prior to baseline. Participants were stratified by sural sensory
nerve action potential (SNAP) amplitude. Participants were trained to use an electronic diary (ED) to record pain. Setting.
Peripheral neuropathies are common complications of HIV infection. The pathogenesis is unknown and currently treatments
are restricted to symptomatic measures. We examined PRO against placebo (PBO) for treatment of painful HIV-SN and
performed a post-hoc evaluation of an electronic diary (ED) to record HIV-associated neuropathic pain. Participants. Eligible
participants included adults with neurologist-confirmed painful HIV-SN. Interventions. 2, 4, 8, or 16 mg/d PRO or PBO
administered via subcutaneous (SC) injection for six weeks. Neurotoxic antiretroviral drug usage was held constant. Outcome
Measures. Changes from baseline in the weekly average of evaluable daily random prompts measuring pain using the Gracely
pain scale and adverse events. Results. 237 participants were randomized. The study was stopped after a planned futility
analysis. There were no between-group differences in the frequency of adverse events or laboratory toxicities. The 6-week
mean (sd) Gracely pain scale changes were 20.12 (0.23), 20.24 (0.35), 20.15 (0.32), 20.18 (0.34), and 20.18 (0.32) for the 2, 4,
8, 16 mg, and PBO arms respectively. A similar variability of pain changes recorded using the ED were noted compared to
previous trials that used paper collection methods. Conclusions. 6-week treatment with PRO was safe but not effective at
reducing HIV-associated neuropathic pain. Use of an ED to record neuropathic pain is novel in HIV-SN, resulted in reasonable
compliance in recording pain data, but did not decrease the variability of pain scores compared to historical paper collection
methods. Trial Registration. ClinicalTrials.gov NCT00286377
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INTRODUCTION
Sensory neuropathy is the most frequent neurological complica-
tion of HIV infection or its treatment with antiretroviral agents.
Despite recent declines in the incidence rates of HIV-associated
dementia and CNS opportunistic infections [1,2] sensory neurop-
athies (HIV-SN) have increased in prevalence to become the most
common neurological disorders associated with AIDS [3]. Two
frequent types of peripheral sensory neuropathy are seen in HIV-
infected patients, distal HIV-associated sensory polyneuropathy
(DSP) and antiretroviral toxic neuropathy (ATN), which together,
affect up to 30% of participants with advanced HIV disease [4,5].
ATN shares most of the clinical features of DSP but is associated
with specific dideoxynucleoside analogue usage and may improve
with discontinuation of the drug.
The most common symptom of HIV-SN is spontaneous or
evoked pain or dysesthetic sensations in the feet. The pathology of
DSP involves a length-dependent degeneration of peripheral nerve
fibers affecting both small and large nerve fibers, but the patho-
genesis is unknown [5–7].
The pathogenesis of ATN is thought to reflect the selective
ability of the dideoxynucleoside analogues to inhibit gamma DNA
polymerase, reduce mitochondrial DNA content, and lead to
mitochondrial dysfunction [8]. Elevated serum lactate levels have
been associated with ATN [9], and mitochondrial DNA levels in
subcutaneous fat obtained by punch skin biopsies are also reduced
after exposure to d4T and ddI [10].
Although patients with HIV-associated neuropathic pain
represent a large and growing participant population, they remain
underserved, with no FDA-approved therapies and relatively few
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measures, with limited efficacy in pain reduction [11]. In addition,
despite the reduced use of these agents in developed countries
because of their toxic effects on the peripheral nervous system,
they remain a critically important component of generic fixed-dose
regimens in resource-limited countries. In fact, world-wide, the
commonest antiretroviral treatment is D4T/3TC/nevaripine.
Thus information about the toxicity of these agents remains
highly relevant.
Saposins are a group of small glycoproteins that activate
lysosomal hydrolysis of a variety of sphingolipids and are mutated
in saposin-deficient human storage diseases. Prosaposin, the
protein precursor of saposin A, B, C, and D, was identified as
a neurotrophic factor. Prosaptide
TM (PRO) is a 14-mer peptide,
synthesized from the neuroactive region of saposin C1–5 [12].
PRO was found to be active in several in vivo neuropathic pain
models [13–15]. PRO has also demonstrated a beneficial effect in
animal models of neuropathy, including both type 1 (streptozo-
tocin) and type 2 (galactose feeding) diabetes, and paclitaxel-
induced toxic neuropathy [12,16–17].
In two phase I clinical trials, subcutaneous injections at doses up
to 300 mg/kg of PRO were found to be safe in healthy controls.
Pharmacokinetic analysis revealed that PRO was rapidly
absorbed, had a short half-life, and showed no accumulation after
repeated dosing.
A randomized, PBO-controlled phase II trial (FDA IND
number 66074) was conducted to study PRO for the relief of
neuropathic pain associated with diabetes mellitus (type 1 or 2).
Three dose levels (1, 4, or 16 mg) of PRO or PBO were self-
administered daily in a double blind fashion for 28 days by
subcutaneous injection (unpublished). A statistically significant
reduction in pain was noted in the 4 mg PRO arm relative to
PBO. Data suggested however that the treatment effect might be
attenuated in severe neuropathies, in which sufficient axonal
degeneration has occurred to render sural SNAP amplitude
undetectable. A similar number of treatment emergent adverse
events were seen in all dose arms including PBO. No participants
develop anti-PRO antibodies. Pharmacokinetic analyses showed
increased blood levels of PRO with increasing dose, with no
evidence of drug accumulation after 28 days of dosing.
Given that PRO was effective in the treatment of neuropathic
pain caused by experimental preclinical animal models of diabetes
or chemotherapy-induced neuropathies, and was also found to be
safe and well-tolerated in early phase clinical trials for diabetic
neuropathy, we conducted a placebo-controlled evaluation of
PRO for the treatment of HIV-associated neuropathic pain. PRO
is not currently in development for any neuropathies, or other
human diseases, and there is no FDA NDA application. This trial
was not part of a registration effort for the compound.
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
This study enrolled adult (.18 years old) male or female
participants with neurologist-confirmed painful HIV-SN (DSP or
ATN). Training in the accurate recognition of HIV-SN was
conducted before the study and the definitional criteria used were
those developed by a consensus conference for the American
Academy of Neurology in 1991 [18]. The duration of the
neuropathy was unknown. We believe that most of the participants
had chronic neuropathic symptoms for at least 6 months. All trial
participants were on a stable antiretroviral regimen prior to entry
and while on the trial.
Entry requirements included: (1) a pain level of Gracely
$0.74 units averaged over the 2-week screening period, (2)
documented HIV-1 infection, (3) stable use or non-use of
dideoxynucleoside reverse transcriptase inhibitors for $4 months,
(4) agreement to limit the use of pain-modifying agents during the
study as specified by the protocol, (5) agreement not to participate
in a conception process, (6) a Karnofsky performance score of
$60, (7) written informed consent, and (8) successful completion of
$75% of ED endpoints in the screening period.
Participants with the following neurologic conditions were
excluded: (1) any condition other than HIV infection or
antiretroviral therapy that could confound the diagnosis of HIV
neuropathy, (2) received insulin or oral hypoglycemic products for
treatment of diabetes mellitus #30 days (dietary control for
diabetes was allowed), (3) a history of documented vitamin B12
deficiency with less than three months of B12 supplementation
prior to screening, (4) hereditary neuropathy, (5) compression-
related neuropathies, (6) use of any drug other than the
dideoxynucleoside analogues that might have significantly con-
tributed to the neuropathy, (7) a history of any alcohol-related
medical complications, (8) neurotoxic chemotherapeutic agents
#90 days before study entry, (9) neuroregenerative agents #90
days before study entry, or (10) presence of myelopathy.
Participants with the following conditions were also excluded: (1)
an active AIDS-defining opportunistic infection (OI) or OI-defining
condition #30 days before study entry, (2) active major disease, both
HIV-related and non-HIV-related including, but not limited to,
cardiac disease, pulmonary, or hepatorenal, (3) pregnant or breast-
feeding, (4) current active malignancy, (5) allergy/sensitivity to PRO,
acetaminophen, or its formulations, (6) received any investigational
agent(s) that is not FDA-approved or has participated in any
interventional research study #30 days before study entry, or (7)
actively using recreational intravenous drugs, crack cocaine, or
intranasal/smoked heroin or methamphetamine.
Participants with the following laboratory abnormalities were also
excluded: (1) absolute neutrophil count (ANC) ,750/mm
3
(,0.756109/L), (2) hemoglobin ,8.0 g/dL for males or ,7.5 g/
dL for females, (3) platelet count ,75,000/mm
3 (,756109/L), (4)
creatinine .1.56upper limit of normal (ULN), (5) AST (SGOT),
ALT (SGPT), and alkaline phosphatase .56 ULN, (6) total
bilirubin .1.56ULN (participants receiving indinavir, atazanavir,
or other drugs with the same known effect on bilirubin levels were
eligible if total bilirubin was ,56ULN), (7) HgbA1C .6.5, or (8)
serum B12 #200 pg/mL. Note that these exclusionary criteria likely
excluded most participants with active hepatitis C coinfection.
Interventions
The intervention in this study was six-week treatment with PRO
or matching placebo for the treatment of HIV-associated
neuropathic pain. The rationale for the 6 weeks duration was
that this was the maximal length of patient exposure allowable by
FDA based on available toxicity data. Participants were randomly
assigned to 2, 4, 8, or 16 mg/d PRO or PBO administered via SC
injection.
Objectives
The objective of this study was to examine the efficacy and safety
of PRO for the treatment of painful HIV-SN compared to PBO
after six weeks of treatment. A post-hoc objective was to evaluate
the use of an ED to record HIV-associated neuropathic pain.
Prosaptide for HIV Neuropathy
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The primary endpoint in this trial was the 6-week change from
baseline in the weekly average of evaluable daily random prompts
measuring pain using the Gracely pain scale. Secondary endpoints
included ‘‘treatment success’’, defined as $0.35 units of pain
improvement from baseline on the Gracely scale, and change in
HIV viral load. Safety endpoints included treatment emergent
serious adverse events (SAEs), AEs, and toxicities.
Sample Size
The study was originally designed to randomize 390 participants,
equally allocated between groups. The study was sized such that the
95% confidence interval for the difference between any dose arm
and PBO with respect to changes in the 13-point Gracely pain scale
was no wider than 0.24 assuming a standard deviation of Gracely
pain scale changes of 0.35 (i.e., an estimate derived from earlier
studies) [19–20]. An interim analysis was planned after 200
participants completed the 6-week double-blind treatment period
to evaluate safety, futility, sample size assumptions made in design of
the trial, and the effect of sural SNAP amplitude on pain changes.
Design
NARC 009/Savient C0603/ACTG A5180 was a prospective,
randomized, double-blind, PBO-controlled, multicenter study. The
study was conducted at member sites of the AIDS Clinical Trials
Group and Neurologic AIDS Research Consortium with neurolog-
ical expertise, and at other community-based trial sites. The study
was approved by all study site Institutional Review Boards.
Participants with at least a moderate pain rating (Gracely pain
scale .0.74) and who had completed written informed consent
were stratified according to sural SNAP amplitude at baseline
(negative: 0–4 :V vs. positive: .4 :V) as a surrogate of baseline
nerve fiber damage and then randomized to 2, 4, 8, or 16 mg/
d PRO or PBO administered via SC injection. A blinded,
centralized laboratory provided quality control by monitoring all
wave forms in sural SNAP amplitudes at each site. The
stratification according to sural SNAP amplitude was made
because the earlier clinical trial in diabetic neuropathy had
suggested a greater therapeutic effect on participants with
detectable sural SNAP amplitude than those with absent sural
SNAP amplitude. The cut-off of 4 microV was made because this
is considered to be lower limit of normal in most electrophysiology
laboratories. Adjuvant pain medications including anticonvulsants,
antidepressants, topical analgesics and short-acting narcotics were
washed out prior to randomization and not permitted during the
study period. Study drug (provided by Savient Pharmaceuticals,
Inc.) was given for six weeks. Neurotoxic antiretroviral drugs were
continued at baseline dosage throughout the study period.
At each site, up to 20% of enrolled participants were permitted
to continue chronic daily doses of long acting opioid analgesics.
The justification for this was that we felt it would be impractical to
safely taper narcotics during a short pre-randomization wash-out
period, and we did not want to completely exclude narcotic-using
participants who met entry criteria in all other regards. All
participants received a supply of acetaminophen 500 mg caplets as
rescue medication. Participants who had intolerable pain despite
rescue medication were permitted to discontinue from the study at
any time.
The study consisted of a two-week washout period, randomi-
zation, a 6-week double-blind treatment period, and a two-week
double-blind cross-over. During the wash-out period, any pain-
modifying agents were tapered and discontinued prior to
randomization. A standardized neurological exam, neuropathy
assessment, and CD4 and HIV-1 RNA evaluations were
performed at baseline and at the end of the double-blind
treatment period. Pain (Gracely pain scale and the Visual
Analogue Scale (VAS)) was measured several times daily.
Randomization-Sequence Generation
The randomization schedule was created using permuted blocks
using a block size of 5 (corresponding to the five treatments).
Randomization was stratified by SNAP status (2 levels: negative:
0–4 :V vs. positive: .4 :V) and was assigned in a ratio of 1:1:1:1:1.
Randomization-Allocation Concealment
Each kit (1 kit per participant) was assigned a kit number. The kit
number could be translated through the randomization sequence
which was stored under lock and key by Savient Quality
Assurance. Randomization was concealed to the clinical sites.
Randomization-Implementation
Generation of the allocation sequence was made by Savient
Pharmaceuticals, Inc. for packaging to site pharmacists. Savient
Quality Assurance Department locked the codes in a secured area.
Site pharmacists assigned patient numbers in a sequential order
and provided appropriate study drug as participants were enrolled
into the study.
Blinding
Study participants, study personnel administering interventions
and assessing outcomes, and investigators were blinded to
treatment assignment. Unblinding occurred only after database
closure. No blinding questionnaire was used.
Electronic Diary
Participants were issued a Palm Pilot ED and trained in its use. The
ED was used to obtain pain data in real time. Data captured on the
ED included the Gracely pain scale, study medication dosing, and
rescue medication use. In addition, a morning assessment of sleep
quality and an evening daily pain score were captured.
Random prompts were presented to the participants approxi-
mately four to six times per day. The participants were asked to
rate their current level of pain using the modified Gracely pain
scale. Functions of the ED included: (1) a ‘‘suspend’’ function
allowing suspension of random prompting for up to two hours, in
anticipation of being in a situation where they should not be
prompted, and (2) a sleep feature enabling participants to ‘‘turn
off’’ the ED during sleep. Prior to each study visit, the participant’s
study compliance in responding to prompts was reported to the
site and used as the basis of providing feedback to study
participants.
Data were uploaded from each ED on a nightly basis by
telephone to a central database. ED programming and data
management was performed by Invivodata, Inc (Pittsburgh, PA).
Statistical Methods
Descriptive statistics were used to describe the study sample and
confidence intervals were used to estimate population parameters.
Graphical methods were used to display changes over time.
Predicted intervals were utilized at the interim futility analysis. The
futility analyses were planned to examine if there was early
evidence that significant results were unlikely, thus providing
a cost-efficiency check. The primary analysis utilized a modified
intent-to-treat (ITT) approach. The ITT population was defined
as all randomized participants that received at least one dose of
Prosaptide for HIV Neuropathy
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imputation was utilized for missing data, however several
sensitivity analyses (e.g., analyses of observed non-missing data)
were performed to ensure the robustness of the results. The signed-
rank test was used to assess the significance of within-arm changes
with respect to continuous variables whereas the Wilcoxon rank
sum test was used to assess between arm differences. Wei-Johnson
tests [21] were used to compare treatment groups across
timepoints. All reported p-values are 2-sided without adjustment
for multiple testing. Statistical significance was assessed using
significance level of 0.05.
RESULTS
Participant Flow, Recruitment, and Numbers
Analyzed
196 of 237 randomized participants from 31 sites completed the
double-blind period (Figure 1). The first participant was enrolled
in August, 2003. 17 participants did not complete the study for
administrative reasons (e.g., early termination of the study in
March, 2005). We report results based on 229 participants that
received study drug (modified ITT population).
Baseline Data
No clinically relevant between-group differences in demographics
or baseline characteristics were observed (Table 1).
Interim Analysis Summary
A planned interim analysis was performed to evaluate safety,
futility, sample size assumptions made in design of the trial, and
the effect of sural SNAP amplitude on pain changes. After
a review of the interim results, the Data Safety Monitoring Board
(DSMB) of the Neurologic AIDS Research Consortium (NARC)
recommended termination of the study based on a futility
analysis which indicated that even if the trial were to continue to
its planned completion with full accrual, there would be a very
low probability of attaining statistical significance with regard to
the analgesia efficacy endpoint for any of the dosing arms
compared to PBO. No safety issues were identified. Sample size
assumptions made in the design phase of the study were
determined to be valid. In particular, the assumed variability of
the change in Gracely pain scale was determined to be
reasonable. Sural SNAP amplitude (the stratification variable)
appeared to have no effect on the change in Gracely pain score
(primary endpoint).
Outcomes and Estimation
Pain decreased in all arms. The 6-week mean (sd) Gracely pain
scale changes (using LOCF) were 20.12 (0.23), 20.24 (0.35),
20.15 (0.32), 20.18 (0.34), and 20.18 (0.32) for the 2, 4, 8,
16 mg, and PBO arms respectively. No statistically significant
differences between any PRO arm and PBO were noted (Figure 2).
LOCF imputation was required on 33/229 (14.4%) observations.
 
 
 
Figure 1. CONSORT Diagram.
doi:10.1371/journal.pone.0000551.g001
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similar results, as did treatment comparisons of pain changes
assessed using the VAS. There was insufficient evidence to
conclude that the ‘‘treatment success’’ rates for the 2 mg (19%),
4 mg (28 %), 8 mg (22 %), and 16 mg (28%), were different from
PBO (22%). The median number of times that rescue medication
was used per day during the study was comparable: placebo (0.26),
2 mg (0.44), 4 mg (0.45), 8 mg (0.48), and 16 mg (0.38).
Table 1. Demographics and Baseline Characteristics by Treatment.
..................................................................................................................................................
Treatment
Total Placebo 2 mg 4 mg 8 mg 16 mg
N 229 45 42 46 46 50
Age (years)
Median 47 46 49 46.5 47.5 47
Q1, Q3 43,53 43, 51 44, 53 45, 54 42, 54 40,53
Race N(%)
American Indian/Alskn Native 1 (0%) 0 (0%) 1 (2%) 0 (0%) 0 (0%) 0 (0%)
White 117 (51%) 24 (53%) 23 (55%) 23 (50%) 22 (48%) 25 (50%)
Black or African American 81 (35%) 15 (33%) 14 (33%) 15 (33%) 20 (43%) 17 (34%)
Hispanic or Latino 27 (12%) 6 (13%) 4 (10%) 7 (15%) 3 (7%) 7 (14%)
Native Hawaiian/Pacific Islndr 1 (0%) 0 (0%) 0 (0%) 1 (2%) 0 (0%) 0 (0%)
Other 2 (1%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 1 (2%)
Sex N(%)
Male 210 (92%) 41 (91%) 41 (98%) 41 (89%) 40 (87%) 47 (94%)
Female 19 (8%) 4 (9%) 1 (2%) 5 (11%) 6 (13%) 3 (6%)
Sural SNAP Amplitude N(%)
.4:V 86 (38%) 17 (38%) 12 (29%) 19 (41%) 17 (37%) 21 (42%)
# 4:V 143 (62%) 28 (62%) 30 (71%) 27 (59%) 29 (63%) 29 (58%)
CD4 (cells/:L)
Median 367 312.5 393.5 447 308 392
Q1, Q3 238, 586 192, 421 260.5, 691 274, 641 214, 565 246, 540
Log10 HIV-1 RNA (copies/mL)
Median 3.06 2.99 3.32 2.90 3.05 3.09
Q1, Q3 2.61, 3.71 2.61, 3.49 2.90, 3.98 2.60, 3.34 2.60, 4.27 2.65, 4.03
Gracely Pain Scale (log, 13 point)
Median 1.22 1.24 1.17 1.16 1.17 1.35
Q1, Q3 1.07, 1.42 1.09, 1.43 0.99, 1.34 1.05, 1.36 1.06, 1.36 1.09, 1.57
VAS Pain Scale
Median 69 69 68.5 65 64.5 73.5
Q1, Q3 59, 78 58.5, 78 57, 76 59, 75 57, 74 62, 84
Continuing on Opioids N(%)
No 210 (92%) 42 (93%) 36 (86%) 41 (89%) 44 (96%) 47 (94%)
Yes 19 (8%) 3 (7%) 6 (14%) 5 (11%) 2 (4%) 3 (6%)
Karnofsky Score N(%)
60 10 (4%) 4 (9%) 0 (0%) 2 (4%) 2 (4%) 2 (4%)
70 28 (12%) 4 (9%) 6 (14%) 3 (7%) 6 (13%) 9 (18%)
80 116 (51%) 21 (47%) 25 (60%) 21 (46%) 25 (54%) 24 (48%)
90 56 (24%) 11 (24%) 9 (21%) 16 (35%) 11 (24%) 9 (18%)
100 19 (8%) 5 (11%) 2 (5%) 4 (9%) 2 (4%) 6 (12%)
ddC, d4T, or ddI Use at Entry N(%)
No 177 (77%) 37 (82%) 33 (79%) 34 (74%) 36 (78%) 37 (74%)
Yes 52 (23%) 8 (18%) 9 (21%) 12 (26%) 10 (22%) 13 (26%)
Weeks on Antiretroviral Therapy at Entry
Median 65 58 88 79 57 59
Q1, Q3 29, 136 29, 93 34, 148 29, 147 26, 116 34, 141
doi:10.1371/journal.pone.0000551.t001
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Five SAEs were reported after the 1
st dose of study drug: two in the
4 mg arm (i. cellulitis, unlikely related (judged by site investigator),
moderate severity, resolved; ii. shigella enteritis, likely unrelated),
one in the 8 mg arm (altered mental status, likely unrelated,
moderate severity, resolved), one in the 16 mg arm (pancreatitis,
likely unrelated, severe, resolved), and one in the PBO arm
(Kaposi’s sarcoma, likely unrelated, mild severity, resolved). No
Figure 2. Difference of Mean Gracely Pain Score Changes (Using LOCF) between each Dosing Group and Placebo across Weeks.
doi:10.1371/journal.pone.0000551.g002
Table 2. Changes in CD4 and Log10 HIV-1 RNA by Treatment.
..................................................................................................................................................
Treatment
Total Placebo 2 mg 4 mg 8 mg 16 mg
CD4 (cells/:L)
N 186 32 37 38 36 43
Median 21.5 23.5 21 10.5 236.5 6
Q1, Q3 265, 39 223, 31 269, 41 256, 40 2101, 10.5 256, 65
p
1 0.25 0.70 0.40 0.99 0.03 0.76
p
2 0.68 0.70 0.07 0.55
Log10 HIV-1 RNA (copies/mL)
N 166 30 36 35 32 33
Median 0.00 20.02 20.06 0.00 20.06 0.00
Q1, Q3 20.27, 0.14 20.25, 0.19 20.34, 0.09 20.10, 0.35 20.47, 0.04 20.18, 0.05
P
1 0.08 0.67 0.07 0.14 0.04 0.22
P
2 0.46 0.18 0.25 0.89
1Signed-rank test for within-arm changes
2Wilcoxon rank sum test vs. placebo
doi:10.1371/journal.pone.0000551.t002
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adverse events or laboratory toxicities between PRO and PBO.
Four grade 3 (severe) AE’s were reported: two in the placebo arm
(i. foot pain, possibly related; ii. thrombocytopenia, possibly
related), one in the 2 mg arm (fatigue, unrelated), and one in the
16 mg arm (thrombocytopenia, unlikely related). Five grade 4
laboratory toxicities were reported: two in the placebo arm (1
reduced platelet count; 2. elevated calcium level), one in the 2 mg
arm (elevated SGOT level), and two in the 16 mg arm (both with
reduced absolute neutrophil count).
Statistically significant decreases in CD4 were noted for the
8 mg arm only; however this was not significantly different
(statistically) from PBO (Table 2). No statistically significant
decreases in plasma HIV-1 RNA levels were noted for the active
compared to PBO.
Ancillary Analyses
Summarization of ED use is based on 11,797 participant-days
(Table 3). 98.05% of all participant-days had a morning report
recorded while within participants, the average response rate was
97.08%. 89.84% of all participant-days had an evening report
while within participants the average response rate was 88.38%.
Forty-four participant-days did not have any random pain
prompts, thus over 11,753 participant-days there were 49,561
random prompts (an average of 4.2 random prompts per day). The
response rate for random prompts was 90.91%. Within partici-
pant-days the average response rate was 91.33% while within
participants the average response rate was 90.37%. Use of study
drugs was reported on 94.59% of all participant-days while within
participants the average medication compliance rate was 92.76%.
28.51% of all participant-days utilized the suspend feature on the
diary at least once while within participants the average percent of
days which used the suspend feature at least once was 28.11%.
The response rate for random prompts was similar for: males
and females (91.03% and 89.44% respectively); white, black, and
other races (92.27%, 88.99%, and 90.55% respectively); and for
younger (# 45 years old) and older (.45 years old) participants
(90.31% and 91.29% respectively).
The standard deviation (SD) of pain changes using the ED
collection method was 0.32.
DISCUSSION
Interpretation
PRO is a novel agent with preclinical evidence suggesting both
analgesic and neuroregenerative potential in painful neuropathy
models. This study was designed to assess only the short term
analgesic potential of PRO, principally because toxicity data was
not available to allow for use over a longer period. This 6-week
treatment with PRO was safe and well tolerated but was not
effective at reducing HIV-associated neuropathic pain relative to
PBO at doses of 2, 4, 8, and 16 mg/day.
Generalizability
The duration of the trial limits any conclusions for the regenerative
potential of PRO, but do not support an acute analgesic effect in
HIV-associated neuropathic pain. This trial was carefully designed
to isolate analgesic effects by removing other pain-modifying
therapies prior to study initiation and restricting the use of opioids.
Our study sample consisted largely of males (92%) as has been
observed on other clinical trials of HIV-SN [19–20,22]. This is not
surprising since HIV-SN tends to affect those with more advanced
HIV disease [23], and proportionately more men than women
have advanced HIV disease in the domestic HIV population.
Overall Evidence
PRO was efficacious in an early trial for diabetic neuropathy. This
clinical trial was the first to examine the effects of PRO for HIV-
associated neuropathy. Results indicated that 6-week treatment
with PRO was safe but not effective at reducing HIV-associated
pain relative to placebo. Possible reasons for the negative nature of
the study include that the mechanism of pain generation in HIV-
SN may be very different from that in diabetic neuropathy. Also,
there was a clear dose effect in the diabetic trial. It is possible that
the doses in the HIV-SN trial were not high enough to observe an
effect. Recently, studies [24] have suggested that protease
inhibitors may be linked to the development of HIV-SN. The
implications of this observation for clinical practice remain unclear
and information is lacking for newer protease inhibitors. Given
that this was a randomized trial, we do not expect that protease
inhibitor use affects our conclusions. The regenerative potential of
PRO is still unknown and it is likely that it could not be
ascertained without a substantially longer trial.
Clinical evaluation of sensory experience, and especially
neuropathic pain is challenging, in part because neuropathic pain
intensity and quality varies considerably within a 24 hour epoch.
Pain treatment trials often rely on paper and pencil tools that are
recorded without observation or verification during treatment, and
which typically attempt to ‘average’ pain during an epoch. The
development of relatively inexpensive personal EDs make avail-
able convenient and affordable technology for prompting
observations and recording responses ‘‘in the moment’’ through-
out a study interval, as well as convenient regular accessing of
responses. With the ability to collect and verify pain data using
frequent observations (e.g., several random prompts per day), it is
possible that a more complete and precise measure of a partic-
ipants’ pain profile may be recorded, resulting in a greater ability
to verify clinical responses. Previous studies have suggested that
EDs can permit much more accurate recording of pain than paper
Table 3. Evaluation of Electronic Diary.
..................................................................................................................................................
Unit of Analysis
Prompt N=49561 Participant Days Participant N=229
Morning Report 98.05% (N=11797) 97.08%
Evening Report 89.84% (N=11797) 88.38%
Random Prompt 90.91% 91.33% (N=11753) 90.37%
Medication Compliance 94.59% (N=11797) 92.76%
Suspend Feature 28.51% (N=11797) 28.11%
doi:10.1371/journal.pone.0000551.t003
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diaries suggested a compliance rate above 91% for the ED
compared to 11% with paper diaries [25]). EDs could enhance the
ability to identify temporal patterns of response to interventions
and to electronically confirm the timing of recorded responses.
Our trial represents the first use of an ED in HIV-SN, and we
initially hypothesized that the ED might reduce variability of
changes in pain measurements over time and might therefore
result in more accurate reporting of changes in pain. However, in
our trial, the ED did not appear to decrease the variability of
Gracely pain changes (SD=0.32) compared to trials that we have
conducted using written diaries (SD=0.33 in ACTG 291 [19] and
ACTG 242 [20]. We note that the variability of the outcome
measure is in part a function of intra-participant variation and also
the lack of effectiveness of study medication. Absent a clear clinical
response to the intervention in this trial, we are limited to
observations about the variability of response, which likely also has
a strong biological basis in the setting of chronic pain. One caveat
is that we did not directly compare ED reports to paper diaries in
the same trial. While we could not confirm a decrease in the
variability in pain assessment using this technology, our experience
did at least support the acceptability of the ED in an HIV-SN
patient population. The ‘‘sleep’’ and ‘‘suspend’’ features of the ED
and the ability to train on its use may improve feasibility for use in
clinical trials. While some participants found the ED device
intrusive and unpleasant, in general they complied very well with it
over this relatively short trial. The study sample included
participants with diverse educational and social backgrounds,
including those with a history of drug abuse. Similar acceptable
compliance with regard to response to random prompts was noted
across demographic subgroups. Thus, we believe that at least for
short periods this technology could be applied in diverse groups of
participants with pain, although the technology would add to the
costs of a trial.
SUPPORTING INFORMATION
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0000551.s001 (0.05 MB
DOC)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0000551.s002 (0.84 MB
DOC)
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